| pubmed-article:10194552 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10194552 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:10194552 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:10194552 | lifeskim:mentions | umls-concept:C0537670 | lld:lifeskim |
| pubmed-article:10194552 | lifeskim:mentions | umls-concept:C0205214 | lld:lifeskim |
| pubmed-article:10194552 | lifeskim:mentions | umls-concept:C0750558 | lld:lifeskim |
| pubmed-article:10194552 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10194552 | pubmed:dateCreated | 1999-6-1 | lld:pubmed |
| pubmed-article:10194552 | pubmed:abstractText | Recombinant human interleukin-11 (rhIL-11) has been shown to enhance recovery from thrombocytopenia and mucosal injury after cancer chemotherapy. Since RNA for the receptor and signal transducer for IL-11 is detected in many cell types including some cancer cells, it was theoretically possible that rhIL-11 could affect the growth of tumor cells. This study was intended to determine whether rhIL-11 stimulates the proliferation of human tumor colony-forming units (TCFUs) taken directly from patients. Tumor cells were cultured in soft agar and continuously exposed to three concentrations of rhIL-11 (1.0, 10.0 and 100.0 U/ml) for 14 days in the capillary cloning system. Growth stimulation was noted in two of 66 (3%) of evaluable specimens, including one of 14 evaluable non-small cell lung cancer and one of five evaluable colon cancer specimens. In these two specimens, there was no increased stimulation of TCFUs with escalating concentrations of rhIL-11. Interestingly, the highest concentration of rhIL-11 tested inhibited the growth of 16 specimens (24.2%; 95% confidence interval 13.9-34.5%). Growth inhibition demonstrated a concentration-response relationship (p < 0.001). These results suggest that rhIL-11 appears unlikely to stimulate the growth of the most common solid tumors. | lld:pubmed |
| pubmed-article:10194552 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10194552 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10194552 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10194552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10194552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10194552 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10194552 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10194552 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10194552 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:SharmaSS | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:Von HoffD DDD | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:GomezLL | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:Ceri?NN | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:LawrenceRR | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:SchaubRR | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:SodaHH | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:RaymondEE | lld:pubmed |
| pubmed-article:10194552 | pubmed:author | pubmed-author:IzbickiMM | lld:pubmed |
| pubmed-article:10194552 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10194552 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:10194552 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10194552 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10194552 | pubmed:pagination | 97-101 | lld:pubmed |
| pubmed-article:10194552 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:meshHeading | pubmed-meshheading:10194552... | lld:pubmed |
| pubmed-article:10194552 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10194552 | pubmed:articleTitle | Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors. | lld:pubmed |
| pubmed-article:10194552 | pubmed:affiliation | Translational Research Laboratory, Institute for Drug Development-Cancer Therapy and Research Center, San Antonio, TX 78229, USA. | lld:pubmed |
| pubmed-article:10194552 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10194552 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
